Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
- PMID: 29234710
- PMCID: PMC5716939
- DOI: 10.1016/j.gore.2017.10.004
Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
Abstract
Background: Tamoxifen is a medication often used for the treatment and prevention of breast cancer. It is classically associated with several gynecological side effects to include a thickened endometrial stripe, increased uterine polyp formation, and an increased risk of uterine cancer. Rarely tamoxifen use has been associated with proliferation of endometriosis often severe enough to mimic a late-stage gynecologic malignancy.
Case: A 62-year-old Gravida 0 postmenopausal female with a medical history of severe obesity, infertility, and preventative tamoxifen use presented for evaluation of gross hematuria. A CT urogram was performed and demonstrated findings concerning for carcinomatosis, likely gynecologic in origin. Cervical cancer screening was up-to-date and she had a negative colonoscopy within the prior 2 years. Serum tumor markers were remarkable only for a mildly elevated CA125 of 37.6. Diagnostic laparoscopy demonstrated apparent operable carcinomatosis limited to the pelvis. The procedure was converted to an exploratory laparotomy, where radical tumor cytoreduction was performed to no gross residual disease. Frozen sections performed intraoperatively were unclear of origin but suggestive of low malignant potential. Final pathology resulted for endometriosis.
Conclusion: This case illustrates a presentation of endometriosis in a postmenopausal woman mimicking advanced mullerian malignancy. The patient's estrogenic state from obesity in combination with the agonist action of the tamoxifen likely contributed to her rare presentation. While findings such as a thickened endometrial stripe are typical of tamoxifen use, such widespread proliferation of endometriosis resulting in a pelvic mass, genito-urinary obstruction, and plaque-like pelvic spread are not.
Précis: Endometriosis is a benign estrogen dependent condition rarely problematic in a postmenopausal patient. Tamoxifen use in the setting of an obese patient may contribute to a proliferation of pre-existing endometriosis which resembles an aggressive late-stage gynecological malignancy.
Figures
References
-
- Bese T., Smsek Y., Bese N., Ilvan S., Arvas M. Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int. J. Gynecol. Cancer. 2003 May–Jun;13(3):376–380. - PubMed
-
- Chang C., Chen P., Leu F. Florid polypoid endometriosis exacervated by tamoxifen therapy in breast cancer. Obstst. Gynecol. 2003:1127e30. - PubMed
-
- Hajjar L.R., Kim W. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case. Obstet. Gynecol. 1993;(4 pt 2 Suppl):624. - PubMed
-
- Karimi Z.M., Behtash N., Sekhavat L., Dehghan A. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review. Asian Pac. J. Cancer Prev. 2009;10(4):595–598. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous